Pegasys Market Report 2026

Pegasys Market Overview

• The Pegasys market growth in the historic period has been driven by increasing prevalence of chronic hepatitis infections, widespread adoption of interferon-based therapies • Market expansion is supported by declining use due to direct-acting antivirals, continued demand in specific patient populations • Growth Driver: Rise In The Prevalence Of Hepatitis B Worldwide Boosts Market • Market Trend: Innovation In Therapies For Polycythemia Vera • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Pegasys Market?

Pegasys is a brand of pegylated interferon alfa-2a used in the treatment of chronic hepatitis B and C, as well as certain types of cancer, including chronic myelogenous leukemia and malignant melanoma. It works by enhancing the body's immune response to fight viral infections and cancer cells and is typically administered via subcutaneous injection, with pegylation extending its half-life for less frequent dosing compared to non-pegylated interferons. The main types of indications for pegasys include chronic hepatitis C and chronic hepatitis B. Chronic hepatitis C is a long-term liver infection caused by the hepatitis C virus (HCV) that can lead to severe liver damage, cirrhosis, or liver cancer if left untreated, and pegasys is used as part of a treatment regimen to manage chronic hepatitis C by boosting the immune response to combat the virus. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies for end users such as hospitals, clinics, ambulatory care, and home care.

What Is The Pegasys Market Growth Forecast?

The growth in the forecast period can be attributed to declining use due to direct-acting antivirals, continued demand in specific patient populations, increasing focus on personalized hepatitis treatment, expansion of emerging market access programs, ongoing clinical research in oncology indications. Major trends in the forecast period include increasing focus on long-acting immunomodulatory therapies, rising preference for reduced-frequency dosing regimens, growing emphasis on combination antiviral treatment protocols, expansion of pegylation-based drug formulations, enhanced monitoring of treatment outcomes.

Global Pegasys Market Segmentation

1) By Indication: Chronic Hepatitis C, Chronic Hepatitis B 2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 3) By End-Users: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Pegasys Market?

The rising prevalence of hepatitis B is anticipated to boost the pegasys market. Hepatitis B refers to a viral infection that attacks the liver, potentially leading to chronic disease, cirrhosis, and liver cancer. The rising prevalence of Hepatitis B is driven by factors such as increased transmission through unprotected sex, intravenous drug use, and inadequate vaccination coverage in certain regions. Pegasys is used to treat hepatitis B by boosting the immune response to control viral replication and reduce liver damage. For instance, in April 2024, according to the European Centre for Disease Prevention and Control, a Sweden-based government health agency, there were 28,855 recorded cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, with an increase of 78% compared to 16,187 cases in the previous year. Additionally, the number of cases in 2022, totaling 28,420, represents a crude rate of 8.5 cases per 100,000 population. Therefore, the rise in the prevalence of hepatitis B worldwide will significantly fuel pegasys industry growth. The rising healthcare expenditure is projected to fuel growth in the pegasys market. Healthcare spending refers to the financial investments made by governments, private sectors, and organizations to support medical services, infrastructure, and public health initiatives. The rising healthcare expenditure globally is driven by factors such as the increasing prevalence of infectious diseases, the need to strengthen healthcare systems, and the commitment to improve public health outcomes. Increasing healthcare expenditure supports the growth of Pegasys by enabling greater investment in antiviral treatments, improving patient access to hepatitis therapies, and expanding funding for advanced biologic medicines. For instance, in May 2024, according to the Office for National Statistics, a UK-based statistics authority, UK healthcare expenditure was around $359.16 billion (£292 billion) in 2023 the total healthcare expenditure increased by 5.6% in nominal terms in 2023. Moreover, in 2022, total long-term health and social care expenditure rose by 2.8% in real terms. Therefore, rising healthcare expenditure boosts growth in the pegasys industry.

Key Players In The Global Pegasys Market

Major companies operating in the pegasys market are Roche Holding AG, pharmaand GmbH

Global Pegasys Market Trends and Insights

A key trend in the pegasys market is focusing on the expansion of specific use cases beyond its initial indications to include treatments such as polycythemia vera (PV) and essential thrombocythemia (ET) to enhance its market presence and patient reach in the oncology and hematology sectors. Pegasys is used to treat polycythemia vera (PV) and essential thrombocythemia (ET) by helping to regulate abnormal blood cell production as part of its expanded use in treating myeloproliferative neoplasms. For instance, in July 2024, pharmaand GmbH (pharma&), an Austria-based pharmaceutical company, received the approval of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), a Type II variation for Pegasys (peginterferon alfa-2a) as a treatment for all eligible patients with polycythemia vera (PV) or essential thrombocythemia (ET). Pegasys is currently approved by the EMA for treating chronic hepatitis B (CHB) in adults and children aged 3 years and older and chronic hepatitis C (CHC) in adults and children aged 5 years and older, in combination with other medicines. However, Pegasys has seen expanded use following its inclusion in independently developed oncology guidelines for myeloproliferative neoplasms (MPNs), PV, and ET.

Regional Insights

North America was the largest region in the pegasys market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Pegasys Market?

The pegasys market consists of sales of monovalent and combination formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pegasys Market Report 2026?

The pegasys market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pegasys industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.